PURPOSE: To review the clinical features, complications, and treatment of Waldenström's
macroglobulinemia, a low-grade lymphoproliferative disorder that produces monoclonal …

Purpose To review the diagnostic criteria, prognostic factors, response criteria, and
treatment options of patients with Waldenstrom's macroglobulinemia (WM). Methods A …

Acclaimed by the worldwide medical community as" a staple reference text in the medical
oncologist's library"(JAMA), DeVita, Hellman, and Rosenberg's Cancer: Principles and …

Background The long-term prognosis for older patients with mantle-cell lymphoma is poor.
Chemoimmunotherapy results in low rates of complete remission, and most patients have a …

PURPOSE In an update of the randomized, open-label, phase III European Mantle Cell
Lymphoma (MCL) Elderly trial (ClinicalTrials. gov identifier: NCT00209209), published in …

In the past 36 months, new developments have occurred both in the understanding of the
biology of Waldenström macroglobulinemia (WM) and in therapeutic options for WM. Here …

Waldenström macroglobulinemia is a B-cell malignancy with lymphoplasmacytic infiltration
in the bone marrow or lymphatic tissue and a monoclonal immunoglobulin M protein (IgM) in …

The spectrum of plasma cell disorders is broad. Monoclonal gammopathy of undetermined
significance and smoldering multiple myeloma are asymptomatic disorders characterized by …

Purpose To evaluate the efficacy and toxicity of single-agent bortezomib in Waldenström's
macroglobulinemia (WM). Patients and Methods Symptomatic WM patients, untreated or …

We report the long-term outcome of a multicenter, prospective study examining fludarabine
and rituximab in Waldenström macroglobulinemia (WM). WM patients with less than 2 prior …